Connect Biopharma Ownership 2024 | Who Owns Connect Biopharma Now?
Institutional Ownership
4257.67%
Insider Ownership
41.27%
Retail Ownership
-4198.94%
Institutional Holders
6.00
Connect Biopharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 3709.47% | 2.22% | 2,043,248 | -18,090 | -0.88% | 3,105,737 | Jun 30, 2024 |
| UBS OCONNOR LLC | 927.16% | 0.05% | 510,701 | - | - | 776,266 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 385.43% | 0.00% | 212,300 | -27,600 | -11.50% | 322,696 | Jun 30, 2024 |
| BLACKROCK INC. | 188.61% | - | 103,891 | -936,176 | -90.01% | 157,914 | Jun 30, 2024 |
| KEUDELL/MORRISON WEALTH MANAGEMENT | 58.46% | 0.01% | 32,200 | 12,500 | 63.45% | 48,944 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 50.76% | - | 27,961 | - | - | 42,500 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 36.31% | - | 20,000 | - | - | 30,000 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 23.06% | - | 12,700 | 12,700 | 100.00% | 19,000 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 17.25% | - | 9,500 | -7,020 | -42.49% | 14,439 | Jun 30, 2024 |
| MORGAN STANLEY | 6.48% | - | 3,568 | 3,568 | 100.00% | 5,423 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.22% | - | 121 | - | - | 184 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.08% | - | 46 | - | - | 70 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -10,805 | -100.00% | - | Jun 30, 2024 |
Connect Biopharma's largest institutional shareholder is BML CAPITAL MANAGEMENT, LLC, holding 3709.47% of the company's total share outstanding, currently valued at $3.11M. The top 10 institutional shareholders own together 5402.98% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 3709.47% | 2.22% | 2,043,248 | -18,090 | -0.88% | 3,105,737 | Jun 30, 2024 |
| UBS OCONNOR LLC | 927.16% | 0.05% | 510,701 | - | - | 776,266 | Jun 30, 2024 |
| KEUDELL/MORRISON WEALTH MANAGEMENT | 58.46% | 0.01% | 32,200 | 12,500 | 63.45% | 48,944 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 385.43% | 0.00% | 212,300 | -27,600 | -11.50% | 322,696 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 36.31% | - | 20,000 | - | - | 30,000 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 17.25% | - | 9,500 | -7,020 | -42.49% | 14,439 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 23.06% | - | 12,700 | 12,700 | 100.00% | 19,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 50.76% | - | 27,961 | - | - | 42,500 | Jun 30, 2024 |
| BLACKROCK INC. | 188.61% | - | 103,891 | -936,176 | -90.01% | 157,914 | Jun 30, 2024 |
| MORGAN STANLEY | 6.48% | - | 3,568 | 3,568 | 100.00% | 5,423 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.08% | - | 46 | - | - | 70 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.22% | - | 121 | - | - | 184 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -10,805 | -100.00% | - | Jun 30, 2024 |
The largest Connect Biopharma shareholder by % of total assets is BML CAPITAL MANAGEMENT, LLC. The company owns 2.04M shares of Connect Biopharma (CNTB), representing 2.22% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | 23.06% | - | 12,700 | 12,700 | 100.00% | 19,000 | Jun 30, 2024 |
| KEUDELL/MORRISON WEALTH MANAGEMENT | 58.46% | 0.01% | 32,200 | 12,500 | 63.45% | 48,944 | Jun 30, 2024 |
| MORGAN STANLEY | 6.48% | - | 3,568 | 3,568 | 100.00% | 5,423 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.22% | - | 121 | - | - | 184 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.08% | - | 46 | - | - | 70 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 50.76% | - | 27,961 | - | - | 42,500 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 36.31% | - | 20,000 | - | - | 30,000 | Jun 30, 2024 |
| UBS OCONNOR LLC | 927.16% | 0.05% | 510,701 | - | - | 776,266 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 17.25% | - | 9,500 | -7,020 | -42.49% | 14,439 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -10,805 | -100.00% | - | Jun 30, 2024 |
| BML CAPITAL MANAGEMENT, LLC | 3709.47% | 2.22% | 2,043,248 | -18,090 | -0.88% | 3,105,737 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 385.43% | 0.00% | 212,300 | -27,600 | -11.50% | 322,696 | Jun 30, 2024 |
| BLACKROCK INC. | 188.61% | - | 103,891 | -936,176 | -90.01% | 157,914 | Jun 30, 2024 |
As of Jun 30 2024, Connect Biopharma's largest institutional buyer is ROYAL BANK OF CANADA. The company purchased 12.70K stocks of CNTB, valued at $19.00K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 188.61% | - | 103,891 | -936,176 | -90.01% | 157,914 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 385.43% | 0.00% | 212,300 | -27,600 | -11.50% | 322,696 | Jun 30, 2024 |
| BML CAPITAL MANAGEMENT, LLC | 3709.47% | 2.22% | 2,043,248 | -18,090 | -0.88% | 3,105,737 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -10,805 | -100.00% | - | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 17.25% | - | 9,500 | -7,020 | -42.49% | 14,439 | Jun 30, 2024 |
| UBS OCONNOR LLC | 927.16% | 0.05% | 510,701 | - | - | 776,266 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 36.31% | - | 20,000 | - | - | 30,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 50.76% | - | 27,961 | - | - | 42,500 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.08% | - | 46 | - | - | 70 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.22% | - | 121 | - | - | 184 | Jun 30, 2024 |
| MORGAN STANLEY | 6.48% | - | 3,568 | 3,568 | 100.00% | 5,423 | Jun 30, 2024 |
| KEUDELL/MORRISON WEALTH MANAGEMENT | 58.46% | 0.01% | 32,200 | 12,500 | 63.45% | 48,944 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 23.06% | - | 12,700 | 12,700 | 100.00% | 19,000 | Jun 30, 2024 |
As of Jun 30 2024, Connect Biopharma's biggest institutional seller is BLACKROCK INC.. The company sold -0.94M shares of CNTB, valued at $157.91K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 6.48% | - | 3,568 | 3,568 | 100.00% | 5,423 | Jun 30, 2024 |
Connect Biopharma's largest new institutional shareholder by number of shares is MORGAN STANLEY, purchased 3.57K shares, valued at $5.42K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | - | - | - | -10,805 | -100.00% | - | Jun 30, 2024 |
Connect Biopharma's largest sold out institutional shareholder by shares sold is TWO SIGMA INVESTMENTS, LP, sold -10.80K shares, valued at -, as of undefined.
Connect Biopharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| BlackRock Health Sciences Trust II | 0.39% | 1,040,067 | - | - | Mar 31, 2024 |
| BlackRock Health Sciences Trust | 0.13% | 33,960 | - | - | Mar 31, 2024 |
| Collaborative Investment Series Trust | 0.09% | 14,588 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.09% | 781,599 | - | - | Jan 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.02% | 219,833 | - | - | Jan 31, 2024 |
| FIDELITY SECURITIES FUND | 0.02% | 1,616,871 | - | - | Jan 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 624,300 | - | - | Feb 29, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.00% | 20,000 | - | - | Mar 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 30,349 | - | - | Feb 29, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 38,093 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 18,062 | - | - | Jan 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 61,749 | - | - | Jan 31, 2024 |
| Federated Hermes Equity Funds | 0.00% | 12,000 | - | - | Jan 31, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 44,354 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 5,044 | - | - | Jan 31, 2024 |
| BlackRock ETF Trust | 0.00% | 211 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 27,961 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 662,152 | - | - | Mar 28, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 5,723 | - | - | Mar 28, 2024 |
| HARTFORD MUTUAL FUNDS INC/CT | 0.00% | 259,682 | - | - | Jan 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 6,208 | - | - | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 276,192 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 3,561 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 785 | - | - | Jan 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 8,985 | - | - | Mar 31, 2024 |
| Fidelity Rutland Square Trust II | 0.00% | 2,900 | - | - | Feb 29, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 111 | - | - | Mar 31, 2024 |
Connect Biopharma's largest mutual fund holder by % of total assets is "BlackRock Health Sciences Trust II", owning 1.04M shares, compromising 0.39% of its total assets.
Connect Biopharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 6 | -45.45% |
| 31 Mar, 24 | 11 | -26.67% |
| 31 Dec, 23 | 15 | 15.38% |
| 30 Sep, 23 | 13 | -13.33% |
| 30 Jun, 23 | 15 | - |
| 31 Mar, 23 | 15 | -21.05% |
| 31 Dec, 22 | 19 | -13.64% |
| 30 Sep, 22 | 22 | -15.38% |
| 30 Jun, 22 | 26 | -7.14% |
| 31 Mar, 22 | 28 | -3.45% |
| 31 Dec, 21 | 29 | 45.00% |
| 30 Sep, 21 | 20 | 25.00% |
| 30 Jun, 21 | 16 | -38.46% |
| 31 Mar, 21 | 26 | - |
As of 30 Jun 24, 6 institutions are holding Connect Biopharma's shares, representing a decrease of -45.45% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 2,345,209 | -40.58% |
| 31 Mar, 24 | 3,947,159 | -44.56% |
| 31 Dec, 23 | 7,119,105 | -29.36% |
| 30 Sep, 23 | 10,078,544 | -2.70% |
| 30 Jun, 23 | 10,358,458 | -5.15% |
| 31 Mar, 23 | 10,920,670 | -6.16% |
| 31 Dec, 22 | 11,636,974 | -8.68% |
| 30 Sep, 22 | 12,742,464 | -14.88% |
| 30 Jun, 22 | 14,969,848 | -15.46% |
| 31 Mar, 22 | 17,707,439 | 4.37% |
| 31 Dec, 21 | 16,966,807 | -12.52% |
| 30 Sep, 21 | 19,395,651 | 1.70% |
| 30 Jun, 21 | 19,072,268 | 23.92% |
| 31 Mar, 21 | 15,391,128 | - |
Connect Biopharma (CNTB) has 2.35M shares outstanding as of 30 Jun 24, down -40.58% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 4257.67% | 8282.02% |
| 31 Mar, 24 | 7.17% | 4.27% |
| 31 Dec, 23 | 12.95% | 3.85% |
| 30 Sep, 23 | 18.33% | 5.16% |
| 30 Jun, 23 | 18.84% | 4.77% |
| 31 Mar, 23 | 19.87% | 4.43% |
| 31 Dec, 22 | 21.17% | 3.94% |
| 30 Sep, 22 | 23.18% | 2.83% |
| 30 Jun, 22 | 28.64% | 2.50% |
| 31 Mar, 22 | 33.87% | 3.22% |
| 31 Dec, 21 | 32.46% | 2.36% |
| 30 Sep, 21 | 37.10% | 2.79% |
| 30 Jun, 21 | 36.49% | 4.21% |
| 31 Mar, 21 | 29.44% | - |
As of 30 Jun 24, Connect Biopharma is held by 4257.67% institutional shareholders, representing a 8282.02% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 1 | -50.00% |
| 31 Mar, 24 | 2 | -71.43% |
| 31 Dec, 23 | 7 | 133.33% |
| 30 Sep, 23 | 3 | -25.00% |
| 30 Jun, 23 | 4 | 33.33% |
| 31 Mar, 23 | 3 | -57.14% |
| 31 Dec, 22 | 7 | -12.50% |
| 30 Sep, 22 | 8 | -50.00% |
| 30 Jun, 22 | 16 | -20.00% |
| 31 Mar, 22 | 20 | -4.76% |
| 31 Dec, 21 | 21 | 110.00% |
| 30 Sep, 21 | 10 | 25.00% |
| 30 Jun, 21 | 8 | -69.23% |
| 31 Mar, 21 | 26 | - |
1 institutional shareholders have increased their position in CNTB stock as of 30 Jun 24 compared to 2 in the previous quarter (a -50.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 3 | -25.00% |
| 31 Mar, 24 | 4 | -33.33% |
| 31 Dec, 23 | 6 | 200.00% |
| 30 Sep, 23 | 2 | -60.00% |
| 30 Jun, 23 | 5 | - |
| 31 Mar, 23 | 5 | -16.67% |
| 31 Dec, 22 | 6 | -40.00% |
| 30 Sep, 22 | 10 | 233.33% |
| 30 Jun, 22 | 3 | -50.00% |
| 31 Mar, 22 | 6 | 20.00% |
| 31 Dec, 21 | 5 | -16.67% |
| 30 Sep, 21 | 6 | 50.00% |
| 30 Jun, 21 | 4 | - |
| 31 Mar, 21 | - | - |
3 institutional shareholders have reduced their position in CNTB stock as of 30 Jun 24 compared to 4 in the previous quarter (a -25.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 6 | -45.45% | 2,345,209 | -40.58% | 4257.67% | 8282.02% | 1 | -50.00% | 3 | -25.00% |
| 31 Mar, 24 | 11 | -26.67% | 3,947,159 | -44.56% | 7.17% | 4.27% | 2 | -71.43% | 4 | -33.33% |
| 31 Dec, 23 | 15 | 15.38% | 7,119,105 | -29.36% | 12.95% | 3.85% | 7 | 133.33% | 6 | 200.00% |
| 30 Sep, 23 | 13 | -13.33% | 10,078,544 | -2.70% | 18.33% | 5.16% | 3 | -25.00% | 2 | -60.00% |
| 30 Jun, 23 | 15 | - | 10,358,458 | -5.15% | 18.84% | 4.77% | 4 | 33.33% | 5 | - |
| 31 Mar, 23 | 15 | -21.05% | 10,920,670 | -6.16% | 19.87% | 4.43% | 3 | -57.14% | 5 | -16.67% |
| 31 Dec, 22 | 19 | -13.64% | 11,636,974 | -8.68% | 21.17% | 3.94% | 7 | -12.50% | 6 | -40.00% |
| 30 Sep, 22 | 22 | -15.38% | 12,742,464 | -14.88% | 23.18% | 2.83% | 8 | -50.00% | 10 | 233.33% |
| 30 Jun, 22 | 26 | -7.14% | 14,969,848 | -15.46% | 28.64% | 2.50% | 16 | -20.00% | 3 | -50.00% |
| 31 Mar, 22 | 28 | -3.45% | 17,707,439 | 4.37% | 33.87% | 3.22% | 20 | -4.76% | 6 | 20.00% |
| 31 Dec, 21 | 29 | 45.00% | 16,966,807 | -12.52% | 32.46% | 2.36% | 21 | 110.00% | 5 | -16.67% |
| 30 Sep, 21 | 20 | 25.00% | 19,395,651 | 1.70% | 37.10% | 2.79% | 10 | 25.00% | 6 | 50.00% |
| 30 Jun, 21 | 16 | -38.46% | 19,072,268 | 23.92% | 36.49% | 4.21% | 8 | -69.23% | 4 | - |
| 31 Mar, 21 | 26 | - | 15,391,128 | - | 29.44% | - | 26 | - | - | - |
CNTB Ownership FAQ
Who Owns Connect Biopharma?
Connect Biopharma is owned by institutional shareholders (4257.67%), insiders (41.27%), and public (-4198.94%). The largest institutional shareholder of Connect Biopharma is BML CAPITAL MANAGEMENT, LLC (3709.47% of total shares) and the top mutual fund owner is BlackRock Health Sciences Trust II (0.39% of total shares).
Who are the major institutional shareholders of Connect Biopharma?
Connect Biopharma's major institutional shareholders are BML CAPITAL MANAGEMENT, LLC, UBS OCONNOR LLC, RENAISSANCE TECHNOLOGIES LLC, BLACKROCK INC., and KEUDELL/MORRISON WEALTH MANAGEMENT. The top five shareholders own together 5269.13% of the company's share outstanding.
How many Connect Biopharma shareholders are there?
As of Jun 2024, there are 6 institutional shareholders of Connect Biopharma.
What percentage of Connect Biopharma is owned by BML CAPITAL MANAGEMENT, LLC?
BML CAPITAL MANAGEMENT, LLC owns 2.04M shares of Connect Biopharma, representing 3709.47% of the company's total shares outstanding, valued at $3.11M (as of Jun 2024).
What percentage of Connect Biopharma is owned by UBS OCONNOR LLC?
As of Jun 2024, UBS OCONNOR LLC holds 510.7K shares of Connect Biopharma (CNTB), compromising 927.16% of the company, valued at $776.27K.
What percentage of Connect Biopharma is owned by RENAISSANCE TECHNOLOGIES LLC?
RENAISSANCE TECHNOLOGIES LLC is the third largest holder of Connect Biopharma. The company owns 212.3K of the company's shares outstanding (worth $322.7K).